Comparing triple vs. dual therapy after liver surgery for liver cancer
Part of Cancer clinical trials.
This trial tests whether adding a third drug to standard two-drug therapy after liver surgery helps prevent liver cancer from returning. It is for people who have a specific blood vessel pattern in their tumor, called VETC, seen on a special stain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have not had any previous treatment (local or by mouth) for liver cancer.
- Your liver function is good (Child-Pugh score of 7 or less).
- You are fully active or able to do light work (ECOG score 0-1).
- You have no serious heart, lung, brain, or kidney disease.
- Your tumor type is hepatocellular carcinoma and shows a VETC blood vessel pattern on a special stain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This trial compares two standard treatments (TACE and HAIC) when combined with an immunotherapy drug (PD-1 inhibitor) and an oral targeted therapy (lenvatinib) for people with liver cancer that cannot be surgically removed. The goal is to see which approach works better in shrinking tumors and improving outcomes.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.